2024-09-03 - Analysis Report
## Vertex Pharmaceuticals (VRTX) Stock Analysis

**Company Overview:** Vertex Pharmaceuticals is a leading biotechnology company focused on developing and commercializing innovative therapies for serious diseases, particularly cystic fibrosis.

**1. Performance vs. S&P 500:**

VRTX has significantly outperformed the S&P 500 (VOO) over the period analyzed, with a cumulative return of 141.66% compared to VOO's 89.66%. The current divergence is 52.0%, which is 91.44% of the historical range. This indicates that VRTX has been outperforming the broader market significantly, although it's important to consider historical context.

**2. Recent Price Movement:**

* **Closing Price:** $495.89
* **5-Day Moving Average:** $488.38
* **20-Day Moving Average:** $478.45
* **60-Day Moving Average:** $482.04

The stock is currently trading above all three moving averages, suggesting a bullish trend in the short-term.

**3. Technical Indicators:**

* **RSI:** 79.95
* **PPO:** 0.39
* **Delta_Previous_Relative_Divergence:** -6.98 (Short-term downtrend)
* **Expected_Return:** 5.46% (Max 5-year expected return)

The RSI is above 70, indicating overbought conditions. The PPO is positive and suggests a potential upward trend. The negative divergence suggests a short-term slowdown, but the expected return remains positive.

**4. Recent Earnings & Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-02 | -13.92 | 2.65 B$ |
| 2024-05-07 | 4.26 | 2.69 B$ |
| 2023-11-07 | 4.01 | 2.48 B$ |
| 2023-08-02 | 3.55 | 2.49 B$ |
| 2024-08-02 | 3.55 | 2.49 B$ |

The most recent earnings report showed a significant EPS decline, but it's crucial to consider the expected EPS and any potential contributing factors. 

**5. Overall Analysis:**

VRTX has been a strong performer, consistently exceeding the broader market. The current price action suggests a short-term bullish trend, although technical indicators point to overbought conditions and a potential slowdown. The recent earnings report, while negative, should be analyzed in the context of expectations and market conditions. 

**6. Summary:**

VRTX continues to be a strong performer, exceeding the S&P 500 by a significant margin.  While technical indicators suggest overbought conditions and a potential short-term slowdown, the stock remains in a bullish trend, and long-term expectations remain positive. Further investigation into the recent earnings report and expected EPS is crucial for a comprehensive analysis. 
